-
公开(公告)号：US11191910B2
公开(公告)日：2021-12-07
申请号：US16695147
申请日：2019-11-25
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Alan Brunelle , Craig Kohring , Christopher Fuller
Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
-
公开(公告)号：US20220105030A1
公开(公告)日：2022-04-07
申请号：US17492136
申请日：2021-10-01
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Kelsey H. Satterly , Stephen B. Shrewsbury , Scott Youmans , Christopher Fuller
IPC: A61K9/00 , A61M11/00 , A61M11/02 , A61M15/00 , A61P25/06 , A61K31/48 , A61K31/522 , A61K47/26 , A61M15/08
Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax(Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
-
公开(公告)号：US20180256836A1
公开(公告)日：2018-09-13
申请号：US15759447
申请日：2016-09-09
Applicant: Impel NeuroPharma, Inc.
Inventor： John D. Hoekman , Christopher Fuller , Craig Kohring
CPC classification number: A61M15/08 , A61M11/02 , A61M15/009 , A61M2210/0618 , A61M2210/005
Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
-
公开(公告)号：US20160101245A1
公开(公告)日：2016-04-14
申请号：US14787455
申请日：2014-04-28
Applicant: IMPEL NEUROPHARMA INC.
Inventor： John D. Hoekman , Alan Brunelle , Craig Kohring , Christopher Fuller
Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
Abstract translation: 用于容纳用于POD装置的鼻内制剂的单位剂量容器。
-
公开(公告)号：US11266799B2
公开(公告)日：2022-03-08
申请号：US15759447
申请日：2016-09-09
Applicant: Impel NeuroPharma, Inc.
Inventor： Christopher Fuller , John D. Hoekman , Craig Kohring
Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20210236485A1
公开(公告)日：2021-08-05
申请号：US17148154
申请日：2021-01-13
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Kelsey H. Satterly , Stephen B. Shrewsbury , Scott Youmans , Christopher Fuller
IPC: A61K31/4985 , A61K9/00 , A61K31/522 , A61K47/26 , A61P25/06
Abstract: Methods are provided for reducing the frequency of migraine attacks in a subject who has frequent migraine headaches with or without aura. The methods comprise intranasally administering to the subject a pharmaceutical composition comprising dihydroergotamine (DHE) or salt thereof on a repeat dose schedule, wherein each intranasal administration is delivered by a manually actuated, propellant-driven, metered-dose administration device, and wherein the schedule is a chronic intermittent schedule in which each of the repeated administrations is performed while the subject is experiencing a migraine headache.
-
公开(公告)号：US11185497B2
公开(公告)日：2021-11-30
申请号：US17062364
申请日：2020-10-02
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Kelsey H. Satterly , Stephen B. Shrewsbury , Scott Youmans , Christopher Fuller
IPC: A61P25/06 , A61K9/00 , A61M11/00 , A61M11/02 , A61M15/00 , A61K31/48 , A61K31/522 , A61K47/26 , A61M15/08
Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
-
公开(公告)号：US20210022995A1
公开(公告)日：2021-01-28
申请号：US17062364
申请日：2020-10-02
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Kelsey H. Satterly , Stephen B. Shrewsbury , Scott Youmans , Christopher Fuller
Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
-
公开(公告)号：US10537692B2
公开(公告)日：2020-01-21
申请号：US14787455
申请日：2014-04-28
Applicant: Impel NeuroPharma Inc.
Inventor： John D. Hoekman , Alan Brunelle , Craig Kohring , Christopher Fuller
Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.
-
公开(公告)号：US20190209463A1
公开(公告)日：2019-07-11
申请号：US16240639
申请日：2019-01-04
Applicant: Impel Neuropharma, Inc.
Inventor： John D. Hoekman , Kelsey H. Satterly , Stephen B. Shrewsbury , Scott Youmans , Christopher Fuller
CPC classification number: A61K9/0043 , A61K31/48 , A61K31/522 , A61K47/26 , A61M15/002 , A61M15/0028 , A61M15/0065 , A61M15/08 , A61P25/06
Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.024 seconds)
